Ovid Therapeutics (OVID) Competitors $0.32 0.00 (-1.19%) As of 09:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OVID vs. VIRI, MIST, BMEA, ORMP, VXRT, CLYM, ADAG, XBIT, JSPR, and BYSIShould you be buying Ovid Therapeutics stock or one of its competitors? The main competitors of Ovid Therapeutics include Virios Therapeutics (VIRI), Milestone Pharmaceuticals (MIST), Biomea Fusion (BMEA), Oramed Pharmaceuticals (ORMP), Vaxart (VXRT), Climb Bio (CLYM), Adagene (ADAG), XBiotech (XBIT), Jasper Therapeutics (JSPR), and BeyondSpring (BYSI). These companies are all part of the "pharmaceutical products" industry. Ovid Therapeutics vs. Its Competitors Virios Therapeutics Milestone Pharmaceuticals Biomea Fusion Oramed Pharmaceuticals Vaxart Climb Bio Adagene XBiotech Jasper Therapeutics BeyondSpring Ovid Therapeutics (NASDAQ:OVID) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, community ranking, risk and valuation. Which has preferable valuation and earnings, OVID or VIRI? Virios Therapeutics has lower revenue, but higher earnings than Ovid Therapeutics. Virios Therapeutics is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOvid Therapeutics$548K40.88-$52.34M-$0.35-0.90Virios TherapeuticsN/AN/A-$5.30M-$0.27-18.26 Does the media prefer OVID or VIRI? In the previous week, Ovid Therapeutics had 3 more articles in the media than Virios Therapeutics. MarketBeat recorded 3 mentions for Ovid Therapeutics and 0 mentions for Virios Therapeutics. Ovid Therapeutics' average media sentiment score of 0.57 beat Virios Therapeutics' score of 0.00 indicating that Ovid Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Ovid Therapeutics Positive Virios Therapeutics Neutral Which has more volatility and risk, OVID or VIRI? Ovid Therapeutics has a beta of 0.08, indicating that its share price is 92% less volatile than the S&P 500. Comparatively, Virios Therapeutics has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500. Do analysts prefer OVID or VIRI? Ovid Therapeutics currently has a consensus target price of $2.78, suggesting a potential upside of 783.60%. Virios Therapeutics has a consensus target price of $3.00, suggesting a potential downside of 39.15%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Ovid Therapeutics is more favorable than Virios Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ovid Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Virios Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the MarketBeat Community believe in OVID or VIRI? Ovid Therapeutics received 356 more outperform votes than Virios Therapeutics when rated by MarketBeat users. Likewise, 71.09% of users gave Ovid Therapeutics an outperform vote while only 50.00% of users gave Virios Therapeutics an outperform vote. CompanyUnderperformOutperformOvid TherapeuticsOutperform Votes35971.09% Underperform Votes14628.91% Virios TherapeuticsOutperform Votes350.00% Underperform Votes350.00% Do institutionals and insiders hold more shares of OVID or VIRI? 72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are held by institutional investors. 13.1% of Ovid Therapeutics shares are held by insiders. Comparatively, 12.2% of Virios Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is OVID or VIRI more profitable? Virios Therapeutics has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -5,142.56%. Ovid Therapeutics' return on equity of -39.24% beat Virios Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Ovid Therapeutics-5,142.56% -39.24% -26.19% Virios Therapeutics N/A -130.33%-115.00% SummaryOvid Therapeutics beats Virios Therapeutics on 14 of the 18 factors compared between the two stocks. Get Ovid Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OVID and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OVID vs. The Competition Export to ExcelMetricOvid TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.40M$6.85B$5.57B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-0.678.7827.1420.06Price / Sales40.88255.49419.32157.08Price / CashN/A65.8538.2534.64Price / Book0.256.557.064.70Net Income-$52.34M$143.93M$3.23B$247.88M7 Day Performance0.54%3.84%2.83%2.63%1 Month Performance4.30%11.20%9.02%6.36%1 Year Performance-90.16%4.18%31.36%14.05% Ovid Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OVIDOvid Therapeutics4.4429 of 5 stars$0.32-1.2%$2.78+783.6%-89.7%$22.40M$548K-0.6760News CoverageGap UpVIRIVirios TherapeuticsN/A$4.89+0.1%$3.00-38.7%+2,104.8%$94.17MN/A-18.115MISTMilestone Pharmaceuticals2.4055 of 5 stars$1.75+1.2%$7.00+300.0%+19.4%$93.56M$1M-2.1630Positive NewsBMEABiomea Fusion3.0355 of 5 stars$2.63+5.6%$21.40+713.7%-43.6%$93.55MN/A-0.6650Positive NewsORMPOramed Pharmaceuticals1.8658 of 5 stars$2.23+0.5%N/A+7.7%$91.10M$2M20.2710Positive NewsVXRTVaxart2.1228 of 5 stars$0.40-2.0%$3.00+655.5%-34.5%$90.66M$47.40M-0.97120Gap UpCLYMClimb Bio3.1206 of 5 stars$1.34-3.6%$9.00+571.6%N/A$90.55MN/A-0.639ADAGAdagene2.7362 of 5 stars$1.91-4.0%$8.00+318.8%-32.0%$89.98M$103.20K0.00260Positive NewsXBITXBiotech1.1334 of 5 stars$2.94+1.4%N/A-57.4%$89.64M$4.01M-2.72100Positive NewsJSPRJasper Therapeutics2.8144 of 5 stars$5.94-1.2%$62.22+947.5%-76.7%$89.23MN/A-1.2520Positive NewsAnalyst RevisionBYSIBeyondSpringN/A$2.21+30.0%N/A+23.3%$89.10M$1.88M0.0080Positive NewsHigh Trading Volume Related Companies and Tools Related Companies VIRI Alternatives MIST Alternatives BMEA Alternatives ORMP Alternatives VXRT Alternatives CLYM Alternatives ADAG Alternatives XBIT Alternatives JSPR Alternatives BYSI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OVID) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored2025 Market Crash50-Year Legend: Here's The Day Stocks Likely Crash Investing legend finds best cycle indicator during 50-ye...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ovid Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ovid Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
